. Afssaps, Suivi cardiométabolique des malades traités par antipsychotiques, Mise au point. Mars, 2010.

N. Afzal and J. Thakore, Stress Axis Dysfunction: A Common Finding in Schizophrenia and the Metabolic Syndrome?, Pharmacopsychiatry, vol.26, pp.82-89, 2009.
DOI : 10.1159/000189776

E. J. Aguilar, C. Leal, and F. J. Acosta, A psychopathological study of a group of schizophrenic patients after attempting suicide. Are there two different clinical subtypes?, European Psychiatry, vol.18, issue.4, pp.190-192, 2003.
DOI : 10.1016/S0924-9338(03)00047-6

K. G. Alberti and P. Zimmet, Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus. Provisional report of a WHO Consultation, Diabetic Medicine, vol.15, issue.7, pp.539-553, 1998.
DOI : 10.1002/(SICI)1096-9136(199807)15:7<539::AID-DIA668>3.0.CO;2-S

K. G. Alberti, P. Zimmet, and J. Shaw, The metabolic syndrome???a new worldwide definition, The Lancet, vol.366, issue.9491, pp.1059-1062, 2005.
DOI : 10.1016/S0140-6736(05)67402-8

C. M. Alexander, P. B. Landsman, S. M. Teutsch, and S. M. Haffner, NCEP-Defined Metabolic Syndrome, Diabetes, and Prevalence of Coronary Heart Disease Among NHANES III Participants Age 50 Years and Older, Diabetes, vol.52, issue.5, pp.1210-1214, 2003.
DOI : 10.2337/diabetes.52.5.1210

D. B. Allison, K. R. Fontaine, and M. Heo, The Distribution of Body Mass Index Among Individuals With and Without Schizophrenia, The Journal of Clinical Psychiatry, vol.60, issue.4, pp.215-220, 1999.
DOI : 10.4088/JCP.v60n0402

D. B. Allison, J. L. Mentore, M. Heo, L. P. Chandler, J. C. Cappelleri et al., Antipsychotic-induced weight gain: a comprehensive research synthesis, American Journal of Psychiatry, vol.156, issue.11, pp.1686-1696, 1999.

D. B. Allison, J. W. Newcomer, A. L. Dunn, J. A. Blumenthal, A. N. Fabricatore et al., Obesity Among Those with Mental Disorders, American Journal of Preventive Medicine, vol.36, issue.4, pp.341-350, 2009.
DOI : 10.1016/j.amepre.2008.11.020

J. A. Ambrose and R. S. Barua, The pathophysiology of cigarette smoking and cardiovascular disease, Journal of the American College of Cardiology, vol.43, issue.10, pp.1731-1738, 2004.
DOI : 10.1016/j.jacc.2003.12.047

G. Institute, S. M. Cleeman, J. I. Daniels, S. R. Donato, K. A. Eckel et al., Diagnosis and management of the metabolic syndrome Executive summary, National Heart, Lung, and Blood Institute Scientific Statement, pp.322-327, 2005.

B. Balkau and M. A. Charles, Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR), Diabetic Medicine, vol.16, pp.442-443, 1999.

B. Balkau, M. Vernay, and L. Mhami, The incidence and persistence of the NCEP (National Cholesterol Education Program) metabolic syndrome. The French D.E.S.I.R. study, Diabetes & Metabolism, vol.29, issue.5, pp.526-532, 2003.
DOI : 10.1016/S1262-3636(07)70067-8

T. Baptista, N. Rangel, V. Fernandez, E. Carrizo, and Y. Fakih, Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: A multicentric, double-blind, placebo-controlled trial, Schizophrenia Research, vol.93, issue.1-3, pp.99-108, 2007.
DOI : 10.1016/j.schres.2007.03.029

P. Barter, A. M. Gotto, J. C. Larosa, J. Maroni, M. Szarek et al., HDL Cholesterol, Very Low Levels of LDL Cholesterol, and Cardiovascular Events, New England Journal of Medicine, vol.357, issue.13, pp.1301-1310, 2007.
DOI : 10.1056/NEJMoa064278

V. S. Basile, M. Masellis, R. S. Mcintyre, H. Y. Meltzer, J. A. Lieberman et al., Genetic dissection of atypical antipsychotic-induced weight gain: novel preliminary data on the pharmacogenetic puzzle, Journal of Clinical Psychiatry, vol.62, issue.S23, pp.45-66, 2001.

C. M. Beasley, Safety of olanzapine, Journal of Clinical Psychiatry Monograph, vol.15, pp.19-21, 1997.

J. Birt, Management of Weight Gain Associated with Antipsychotics, Annals of Clinical Psychiatry, vol.15, issue.1, pp.49-53, 2003.
DOI : 10.3109/10401230309085669

P. Bjorntorp, Heart and Soul: Stress and the Metabolic Syndrome, Scandinavian Cardiovascular Journal, vol.7, issue.83, pp.172-177, 2001.
DOI : 10.1056/NEJM199902113400607

D. W. Black and R. Fisher, Mortality in DSM-IIIR schizophrenia, Schizophrenia Research, vol.7, issue.2, pp.109-116, 1992.
DOI : 10.1016/0920-9964(92)90040-C

S. N. Blair, J. B. Kampert, and H. W. Kohl, Influences of Cardiorespiratory Fitness and Other Precursors on Cardiovascular Disease and All-Cause Mortality in Men and Women, 1996.

J. Bobes, C. Arango, P. Aranda, R. Carmena, M. Garcia-garcia et al., Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: Results of the CLAMORS Study, Schizophrenia Research, vol.90, issue.1-3, pp.162-173, 2007.
DOI : 10.1016/j.schres.2006.09.025

J. Bobes, C. Arango, P. Aranda, R. Carmena, M. Garcia-garcia et al., Healthy lifestyle habits and 10-year cardiovascular risk in schizophrenia spectrum disorders: An analysis of the impact of smoking tobacco in the CLAMORS schizophrenia cohort, Schizophrenia Research, vol.119, issue.1-3, pp.101-109, 2010.
DOI : 10.1016/j.schres.2010.02.1030

D. W. Bonhaus, K. K. Weinhardt, M. Taylor, A. Desouza, P. M. Mcneeley et al., RS-102221: A Novel High Affinity and Selective, 5-HT2C Receptor Antagonist, Neuropharmacology, vol.36, issue.4-5, pp.4-5, 1997.
DOI : 10.1016/S0028-3908(97)00049-X

F. Bonnet and M. Laville, Le syndrome métabolique : Définition, épidémiologie, complications, Spectra Biologie, vol.145, pp.27-29, 2005.

V. P. Bozikas, M. Papakosta, and I. Niopas, Smoking impact on CYP1A2 activity in a group of patients with schizophrenia, European Neuropsychopharmacology, vol.14, issue.1, pp.39-44, 2004.
DOI : 10.1016/S0924-977X(03)00061-0

T. Brömel, W. F. Blum, A. Ziegler, E. Schulz, M. Bender et al., Serum leptin levels increase rapidly after initiation of clozapine therapy, Molecular Psychiatry, vol.3, issue.1, pp.76-80, 1998.
DOI : 10.1038/sj.mp.4000352

S. Brown, J. Birtwistle, L. Roe, and C. Thompson, The unhealthy lifestyle of people with schizophrenia, Psychological Medicine, vol.29, issue.3, pp.697-701, 1999.
DOI : 10.1017/S0033291798008186

S. Brown, Excess mortality of schizophrenia. A meta-analysis, The British Journal of Psychiatry, vol.171, issue.6, pp.502-508, 1997.
DOI : 10.1192/bjp.171.6.502

S. Brown, H. Inskip, and B. Barraclough, Causes of the excess mortality of schizophrenia, The British Journal of Psychiatry, vol.177, issue.3, pp.212-217, 2000.
DOI : 10.1192/bjp.177.3.212

C. Brown and J. Goetz, A psychiatric rehabilitation approach to weight loss., Psychiatric Rehabilitation Journal, vol.29, issue.4, pp.267-273, 2006.
DOI : 10.2975/29.2006.267.273

S. Brown, M. Kim, C. Mitchell, and H. Inskip, Twenty-five year mortality of a community cohort with schizophrenia, The British Journal of Psychiatry, vol.196, issue.2, pp.116-121, 2010.
DOI : 10.1192/bjp.bp.109.067512

P. F. Buckley, D. D. Miller, and B. Singer, Clinicians' recognition of the metabolic adverse effects of antipsychotic medications, Schizophrenia Research, vol.79, issue.2-3, pp.281-289, 2005.
DOI : 10.1016/j.schres.2005.04.010

C. Bushe and R. Holt, Prevalence of diabetes and impaired glucose tolerance in patients with schizophrenia, The British Journal of Psychiatry, vol.184, issue.47, pp.67-71, 2004.
DOI : 10.1192/bjp.184.47.s67

R. C. Callaghan, S. Veldhuisen, T. Jeysingh, C. Orlan, C. Graham et al., Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression, Journal of Psychiatric Research, vol.48, issue.1, pp.102-110, 2014.
DOI : 10.1016/j.jpsychires.2013.09.014

R. M. Capasso, T. W. Lineberry, and J. M. Bostwick, Mortality in schizophrenia and schizoaffective disorder: an Olmsted County, Minnesota cohort, Schizophrenia Research, vol.98, pp.1950-2005, 2008.

D. E. Casey, Dyslipidemia and atypical antipsychotic drugs, Journal of Clinical Psychiatry, vol.65, pp.27-35, 2004.

D. E. Casey, Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia, Journal of Clinical Psychiatry, vol.65, issue.S7, pp.4-18, 2004.

D. E. Casey, Metabolic issues and cardiovascular disease in patients with psychiatric disorders, The American Journal of Medicine Supplements, vol.118, pp.15-22, 2005.
DOI : 10.1016/j.amjmed.2005.01.046

Y. C. Chagnon, A. Bureau, D. Gendron, R. H. Bouchard, C. Merette et al., Possible association of the pro-melanin-concentrating hormone gene witha greater body mass index as a side effect of the antipsychotic olanzapine, American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol.83, issue.8, pp.1063-1069, 2007.
DOI : 10.1002/ajmg.b.30554

L. Citrome, Metabolic Syndrome and Cardiovascular Disease, Journal of Psychopharmacology, vol.19, issue.6 suppl, pp.84-93, 2005.
DOI : 10.1177/0269881105058375

L. Citrome, The metabolic syndrome: time for a critical appraisal, Response to Kahn et al. Diabetes Care 29, 2006.

L. Citrome and B. Vreeland, Obesity and mental illness. Mod Trends Pharmacopsychiatry 26, pp.25-46, 2009.

P. G. Clifton, M. D. Lee, and C. T. Dourish, Similarities in the action of Ro 60-0175, a 5-HT2C receptor agonist, and d-fenfluramine on feeding patterns in the rat, Psychopharmacology, vol.152, issue.3, pp.256-267, 2000.
DOI : 10.1007/s002130000504

M. E. Cohen, B. Dembling, and J. B. Schorling, The association between schizophrenia and cancer: a population-based mortality study, Schizophrenia Research, vol.57, issue.2-3, pp.139-146, 2002.
DOI : 10.1016/S0920-9964(01)00308-5

T. Cohn, D. Prud-'homme, D. Streiner, H. Kameh, G. Remington et al., Characterizing coronary heart disease risk in chronic schizophrenia: high prevalence of the metabolic Relation of impaired fasting and postload glucose with incident type 2 diabetes in a Dutch population: the Hoorn study, JAMA, vol.285, pp.2109-2113, 2001.

F. B. Dickerson, C. H. Brown, and G. L. Daumit, Health Status of Individuals With Serious Mental Illness, Schizophrenia Bulletin, vol.32, issue.3, pp.584-589, 2006.
DOI : 10.1093/schbul/sbj048

F. B. Dickerson, C. H. Brown, J. A. Kreyenbuhi, L. Fang, R. W. Goldberg et al., Obesity among individuals with serious mental illness, Acta Psychiatrica Scandinavica, vol.173, issue.2, pp.306-313, 2006.
DOI : 10.1038/sj.ijo.0802204

L. Dixon, L. Postrado, and J. Delahanty, The Association of Medical Comorbidity in Schizophrenia with Poor Physical and Mental Health, The Journal of Nervous & Mental Disease, vol.187, issue.8, pp.496-502, 1999.
DOI : 10.1097/00005053-199908000-00006

C. T. Dourish, P. H. Hutson, and G. Curzon, Low doses of the putative serotonin agonist 8-hydroxy-2-(di-n-propylamino) tetralin (8-OH-DPAT) elicit feeding in the rat, Psychopharmacology, vol.30, issue.1-2, pp.1-2, 1985.
DOI : 10.1007/BF00431709

B. G. Druss, D. W. Bradford, and R. A. Rosenheck, Mental Disorders and Use of Cardiovascular Procedures After Myocardial Infarction, JAMA, vol.283, issue.4, pp.506-511, 2000.
DOI : 10.1001/jama.283.4.506

F. Duval, Affections m??taboliques et psychiatrie, EMC - Psychiatrie, vol.10, issue.2, 2013.
DOI : 10.1016/S0246-1072(13)60022-X

D. Einhorn, G. M. Reaven, and R. H. Cobin, American college of Endocrinology position statement on the insulin resistance syndrome, Endocrine Practice, vol.9, pp.237-252, 2003.

M. Esler, C. Ferrier, G. Lambert, G. Eisenhofer, H. Cox et al., Biochemical evidence of sympathetic hyperactivity in human hypertension., Hypertension, vol.17, issue.4_Suppl, pp.29-35, 1991.
DOI : 10.1161/01.HYP.17.4_Suppl.III29

G. Faulkner, T. Cohn, and G. Remington, Validation of a physical activity assessment tool for individuals with schizophrenia, Schizophrenia Research, vol.82, issue.2-3, pp.225-231, 2006.
DOI : 10.1016/j.schres.2005.10.020

M. Fava, Weight gain and antidepressants, Journal of Clinical Psychiatry, vol.61, issue.S11, pp.37-41, 2000.

M. H. Fernstrom, L. H. Epstein, D. G. Spiker, and D. J. Kupfer, Resting metabolic rate is reduced in patients treated with antidepressants, Biological Psychiatry, vol.20, issue.6, pp.692-695, 1985.
DOI : 10.1016/0006-3223(85)90107-6

E. S. Ford, The metabolic syndrome and mortality from cardiovascular disease and allcauses: findings from the National Health and Nutrition Examination Survey III Mortality Study, Atherosclerosis, vol.173, pp.309-314, 2004.

E. S. Ford, W. H. Giles, and A. H. Mokdad, Increasing Prevalence of the Metabolic Syndrome Among U.S. Adults, Diabetes Care, vol.27, issue.10, pp.2444-2453, 2004.
DOI : 10.2337/diacare.27.10.2444

J. I. Friedman, S. Wallenstein, and E. Moshier, The Effects of Hypertension and Body Mass Index on Cognition in Schizophrenia, American Journal of Psychiatry, vol.167, issue.10, pp.1232-1239, 2010.
DOI : 10.1176/appi.ajp.2010.09091328

E. J. Garland, R. A. Remick, and A. P. Zis, Weight Gain with Antidepressants and Lithium, Journal of Clinical Psychopharmacology, vol.8, issue.5, pp.323-353, 1988.
DOI : 10.1097/00004714-198810000-00003

A. Gastaldelli, A. M. Sironi, D. Ciociaro, V. Positano, E. Buzzigoli et al., Visceral fat and beta cell function in non-diabetic humans, Diabetologia, vol.113, issue.Suppl 1, pp.2090-2096, 2005.
DOI : 10.1007/s00125-005-1891-3

T. P. George, D. M. Ziedonis, and A. Feingold, Nicotine Transdermal Patch and Atypical Antipsychotic Medications for Smoking Cessation in Schizophrenia, American Journal of Psychiatry, vol.157, issue.11, pp.1835-1842, 2000.
DOI : 10.1176/appi.ajp.157.11.1835

T. P. George, J. C. Vessichio, and A. Termine, Nicotine and tobacco use in schizophrenia, Medical illness and schizophrenia, pp.163-83, 2003.

J. Gill and D. Malkova, Physical activity, fitness and cardiovascular disease risk in adults: interactions with insulin resistance and obesity, Clinical Science, vol.110, issue.4, pp.409-425, 2006.
DOI : 10.1042/CS20050207

C. J. Girman, J. M. Dekker, T. Rhodes, G. Nijpels, C. D. Stehouwer et al., An exploratory analysis of criteria for the metabolic syndrome and its prediction of, 2005.

C. Gury, Schizophrenia, diabètes mellitus and antipsychotics, pp.382-391, 2004.

R. Haghighat, A unitary theory of stigmatisation: Pursuit of self-interest and routes to destigmatisation, The British Journal of Psychiatry, vol.178, issue.3, pp.207-215, 2001.
DOI : 10.1192/bjp.178.3.207

S. Hägg, L. Joelsson, T. Mjörndall, O. Spigset, G. Oja et al., Prevalence of Diabetes and Impaired Glucose Tolerance in Patients Treated With Clozapine Compared With Patients Treated With Conventional Depot Neuroleptic Medications, The Journal of Clinical Psychiatry, vol.59, issue.6, pp.294-303, 1998.
DOI : 10.4088/JCP.v59n0604

S. Hagg, Y. Lindblow, T. Mjorndal, and R. Adolfsson, High prevalence of the metabolic syndrome among a Swedish cohort of patients with schizophrenia, International Clinical Psychopharmacology, vol.21, pp.93-98, 2006.

R. L. Hanson, G. Imperatore, and P. H. Bennett, Components of the "Metabolic Syndrome" and Incidence of Type 2 Diabetes, Diabetes, vol.51, issue.10, pp.3120-3127, 2002.
DOI : 10.2337/diabetes.51.10.3120

J. M. Harkavy-friedman, K. Restifo, and D. Malaspina, Suicidal behavior in schizophrenia: characteristics of individuals who had and had not attempted suicide, American Journal of Psychiatry, vol.156, pp.1276-1278, 1999.

E. Harris and B. Barraclough, Excess mortality of mental disorder, The British Journal of Psychiatry, vol.173, issue.1, pp.11-53, 1998.
DOI : 10.1192/bjp.173.1.11

M. Vieweg, W. V. Fredrickston, and S. K. , Clinical monitoring and management of the metabolic syndrome in patients receiving atypical antipsychotic medications, Primary Care Diabetes, vol.3, pp.5-15, 2009.

M. Hasnain, S. K. Fredrickson, W. V. Vieweg, and A. K. Et-panduragi, Metabolic Syndrome Associated with Schizophrenia and Atypical Antipsychotics, Current Diabetes Reports, vol.58, issue.Suppl 1, pp.209-216, 2010.
DOI : 10.1007/s11892-010-0112-8

P. R. Hebert, M. J. Gaziano, and K. S. Chan, Cholesterol Lowering With Statin Drugs, Risk of Stroke, and Total Mortality, JAMA, vol.278, issue.4, pp.313-321, 1997.
DOI : 10.1001/jama.1997.03550040069040

D. C. Henderson, E. Cagliero, C. Gray, R. A. Nasrallah, D. L. Hayden et al., Clozapine, Diabetes Mellitus, Weight Gain, and Lipid Abnormalities: A Five-Year Naturalistic Study, American Journal of Psychiatry, vol.157, issue.6, pp.975-981, 2000.
DOI : 10.1176/appi.ajp.157.6.975

D. C. Henderson, D. D. Nguyen, P. M. Copeland, D. L. Hayden, C. P. Borba et al., Clozapine, Diabetes Mellitus, Hyperlipidemia, and Cardiovascular Risks and Mortality, The Journal of Clinical Psychiatry, vol.66, issue.09, pp.1116-1121, 2005.
DOI : 10.4088/JCP.v66n0905

C. H. Hennekens, Increasing Burden of Cardiovascular Disease : Current Knowledge and Future Directions for Research on Risk Factors, Circulation, vol.97, issue.11, pp.1095-1102, 1998.
DOI : 10.1161/01.CIR.97.11.1095

C. H. Hennekens, Clinical and research challenges in risk factors for cardiovascular diseases, European Heart Journal, vol.21, issue.23, pp.1917-1921, 2000.
DOI : 10.1053/euhj.1999.2221

C. H. Hennekens, A. R. Hennekens, and D. Hollar, Schizophrenia and increased risks of cardiovascular disease, American Heart Journal, vol.150, issue.6, pp.1115-1121, 2005.
DOI : 10.1016/j.ahj.2005.02.007

D. Hinze-selch, A. Schuld, T. Kraus, M. Kühn, M. Uhr et al., Effects of Antidepressants on Weight and on the Plasma Levels of Leptin, TNF-?? and Soluble TNF Receptors A Longitudinal Study in Patients Treated with Amitriptyline or Paroxetine, Neuropsychopharmacology, vol.23, issue.1, pp.13-19, 2000.
DOI : 10.1016/S0893-133X(00)00089-0

P. Homel, D. Casey, and D. B. Allison, Changes in body mass index for individuals with and without schizophrenia, 1987???1996, Schizophrenia Research, vol.55, issue.3, pp.277-284, 1987.
DOI : 10.1016/S0920-9964(01)00256-0

K. L. Houseknecht, A. S. Robertson, W. Zadavoski, E. M. Gibbs, D. E. Johnson et al., Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects, Neuropsychopharmacology, vol.72, issue.2, pp.289-297, 2007.
DOI : 10.1038/sj.npp.1301209

Y. Hu, A. J. Young, E. A. Ehli, D. Nowotny, P. S. Davies et al., Metformin and berberine prevent olanzapine-induces weight gain in rats, PloS One, vol.9, pp.377-382, 2014.

B. Isomaa, P. Almgren, and T. Tuomi, Cardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome, Diabetes Care, vol.24, issue.4, pp.683-689, 2001.
DOI : 10.2337/diacare.24.4.683

D. C. Javitt, Treatment of negative and cognitive symptoms, Current Psychiatry Reports, vol.18, issue.Suppl 2, pp.25-30, 1999.
DOI : 10.1007/s11920-999-0007-z

J. Jeppesen, H. O. Hein, P. Suadicani, and F. Gyntelberg, Triglyceride Concentration and Ischemic Heart Disease : An Eight-Year Follow-up in the Copenhagen Male Study, Circulation, vol.97, issue.11, pp.1029-1036, 1998.
DOI : 10.1161/01.CIR.97.11.1029

H. Jin, J. M. Meyer, S. Mudaliar, and D. V. Et-jetse, Impact of atypical antipsychotic therapy on leptin, ghrelin, and adiponectin, Schizophrenia Research, vol.100, issue.1-3, pp.70-85, 2008.
DOI : 10.1016/j.schres.2007.11.026

D. A. Johnson, Studies of depressive symptoms in schizophrenia, The British Journal of Psychiatry, vol.139, issue.2, pp.89-101, 1981.
DOI : 10.1192/bjp.139.2.89

R. Kahn, J. Buse, E. Ferrannini, and M. Stern, The metabolic syndrome: time for a critical appraisal, Diabetologia, vol.28, issue.9, pp.1684-99, 2005.
DOI : 10.1007/s00125-005-1876-2

D. Kalman, S. B. Morissette, and T. P. George, Co-Morbidity of Smoking in Patients with Psychiatric and Substance Use Disorders, American Journal on Addictions, vol.14, issue.2, pp.106-123, 2005.
DOI : 10.1080/10550490590924728

M. M. Kato and P. J. Goodnick, Antipsychotic medication: effects on regulation of glucose and lipids, Expert Opinion on Pharmacotherapy, vol.156, issue.10, pp.1571-1582, 2001.
DOI : 10.1016/S0033-3182(99)71210-7

P. E. Keck and S. L. Mc-elroy, Bipolar Disorder, Obesity, and Pharmacotherapy-Associated Weight Gain, The Journal of Clinical Psychiatry, vol.64, issue.12, pp.1426-1435, 2003.
DOI : 10.4088/JCP.v64n1205

P. E. Keck and S. L. Mcelroy, Aripiprazole: a partial dopamine D2 receptor agonist antipsychotic, Expert Opinion on Investigational Drugs, vol.12, issue.4, pp.655-662, 2003.
DOI : 10.1517/eoid.12.4.655.23750

W. C. Knowler, E. Barret-connor, S. E. Fowler, R. F. Hamman, J. M. Lachin et al., Reduction in the incidence of type 2-diabetes with lifestyle intervention or metformin, New England Journal of Medicine, vol.346, pp.393-403, 2002.

E. Koller, B. Schneider, K. Bennett, and G. Et-dubitsky, Clozapine-associated diabetes, The American Journal of Medicine, vol.111, issue.9, pp.716-723, 2001.
DOI : 10.1016/S0002-9343(01)01000-2

C. E. Koro, D. O. Fedder, G. J. L-'italien, S. S. Weiss, L. S. Magder et al., Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: population based nested case-control study, BMJ, vol.325, issue.7358, pp.325-243, 2002.
DOI : 10.1136/bmj.325.7358.243

T. R. Kosten and T. Ziedonis, Substance Abuse and Schizophrenia: Editors' Introduction, Schizophrenia Bulletin, vol.23, issue.2, pp.181-186, 1997.
DOI : 10.1093/schbul/23.2.181

URL : http://schizophreniabulletin.oxfordjournals.org/cgi/content/short/23/2/181

P. Kurdyak, S. Vigod, A. Calzavara, and W. P. Wodchis, High mortality and low access to care following incident acute myocardial infarction in individuals with schizophrenia, Schizophrenia Research, vol.142, issue.1-3, pp.52-57, 2012.
DOI : 10.1016/j.schres.2012.09.003

B. L. Lambert, C. H. Chou, and K. Y. Chang, Antipsychotic exposure and type 2 diabetes among patients with schizophrenia: a matched case-control study of California Medicaid claims, Pharmacoepidemiology and Drug Safety, vol.158, issue.6, pp.417-425, 2005.
DOI : 10.1002/pds.1092

J. S. Lamberti, T. Bellnier, and S. B. Schwarzkopf, Weight gain among schizophrenic patients treated with clozapine, American Journal of Psychiatry, vol.149, pp.689-690, 1992.

K. Lasser, J. W. Boyd, S. Woolhandler, D. U. Himmelstein, D. Mc-cormick et al., Smoking and Mental Illness, JAMA, vol.284, issue.20, pp.2606-2610, 2000.
DOI : 10.1001/jama.284.20.2606

T. Laursen, T. Munk-olsen, M. Nordentoft, and P. Mortensen, Increased Mortality Among Patients Admitted With Major Psychiatric Disorders, The Journal of Clinical Psychiatry, vol.68, issue.06, pp.899-907, 2007.
DOI : 10.4088/JCP.v68n0612

T. M. Laursen, T. Munk-olsen, E. Agerbo, C. Gasse, and P. B. Mortensen, Somatic Hospital Contacts, Invasive Cardiac Procedures, and Mortality From Heart Disease in Patients With Severe Mental Disorder, Archives of General Psychiatry, vol.66, issue.7, pp.713-720, 2009.
DOI : 10.1001/archgenpsychiatry.2009.61

T. M. Laursen, Life expectancy among persons with schizophrenia or bipolar affective disorder, Schizophrenia Research, vol.131, issue.1-3, pp.101-104, 2011.
DOI : 10.1016/j.schres.2011.06.008

D. Lawrence, C. Holman, A. Jablensky, and M. Hobbs, Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998, The British Journal of Psychiatry, vol.182, issue.1, pp.31-36, 2003.
DOI : 10.1192/bjp.182.1.31

S. Leucht, S. Wagenpfeil, J. Hamann, and W. Et-kissling, Amisulpride is an ?atypical? antipsychotic associated with low weight gain, Psychopharmacology, vol.173, issue.1-2, pp.112-115, 2004.
DOI : 10.1007/s00213-003-1721-6

S. Leucht, T. Burkard, and J. Henderson, Physical illness and schizophrenia: a review of the literature, Acta Psychiatrica Scandinavica, vol.63, issue.9, pp.317-333, 2007.
DOI : 10.1016/S0920-9964(02)00314-6

S. Leucht, C. Corves, D. Arbter, R. R. Engel, L. et al., Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis, The Lancet, vol.373, issue.9657, pp.31-41, 2009.
DOI : 10.1016/S0140-6736(08)61764-X

S. Lev-ran, L. Strat, Y. , L. Foll, and B. , Impact of Hypertension and Body Mass Index on Quality of Life in Schizophrenia, American Journal of Psychiatry, vol.168, issue.5, pp.552-555, 2011.
DOI : 10.1176/appi.ajp.2011.10101470

D. Lichtermann, J. Ekelund, and E. Pukkala, Incidence of Cancer Among Persons With Schizophrenia and Their Relatives, Archives of General Psychiatry, vol.58, issue.6, pp.573-581, 2001.
DOI : 10.1001/archpsyc.58.6.573

J. A. Lieberman and T. S. Stroup, Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia, New England Journal of Medicine, vol.353, issue.12, pp.1209-1223, 2005.
DOI : 10.1056/NEJMoa051688

J. P. Lindenmayer, P. Czobor, J. Volavka, L. Citrome, B. Sheitman et al., Changes in Glucose and Cholesterol Levels in Patients With Schizophrenia Treated With Typical or Atypical Antipsychotics, American Journal of Psychiatry, vol.160, issue.2, pp.290-296, 2003.
DOI : 10.1176/appi.ajp.160.2.290

J. P. Lindenmayer, A. Khan, A. Iskander, M. T. Abad, and B. Parker, A Randomized Controlled Trial of Olanzapine Versus Haloperidol in the Treatment of Primary Negative Symptoms and Neurocognitive Deficits in Schizophrenia, The Journal of Clinical Psychiatry, vol.68, issue.03, pp.368-379, 2007.
DOI : 10.4088/JCP.v68n0303

J. B. Lohr and K. Flynn, Smoking and schizophrenia, Schizophrenia Research, vol.8, issue.2, pp.93-102, 1992.
DOI : 10.1016/0920-9964(92)90024-Y

C. Lorenzo, K. Williams, K. J. Hunt, and S. M. Haffner, The National Cholesterol Education Program-Adult Treatment Panel III, International Diabetes Federation, and World Health Organization Definitions of the Metabolic Syndrome as Predictors of Incident Cardiovascular Disease and Diabetes, Diabetes Care, vol.30, issue.1, pp.8-13, 2007.
DOI : 10.2337/dc06-1414

F. H. Luyckx and A. J. Scheen, Le syndrome métabolique : comparaison des paramètres biologiques dans différentes définitions. Immuno-ananlyse et biologie spécialisée 19, pp.188-194, 2004.
DOI : 10.1016/j.immbio.2004.03.008

C. G. Lyketsos, G. Dunn, M. J. Kaminsky, and W. R. Breakey, Medical Comorbidity in Psychiatric Inpatients: Relation to Clinical Outcomes and Hospital Length of Stay, Psychosomatics, vol.43, issue.1, pp.24-30, 2002.
DOI : 10.1176/appi.psy.43.1.24

P. Marques-vidal, E. Mazoyer, and V. Bongard, Prevalence of Insulin Resistance Syndrome in Southwestern France and Its Relationship With Inflammatory and Hemostatic Markers, Diabetes Care, vol.25, issue.8, pp.1371-1377, 2002.
DOI : 10.2337/diacare.25.8.1371

R. G. Mccreadie, Diet, smoking and cardiovascular risk in people with schizophrenia: Descriptive study, The British Journal of Psychiatry, vol.183, issue.6, pp.534-539, 2003.
DOI : 10.1192/bjp.183.6.534

J. P. Mcevoy, O. Freudenreich, and M. Mcgee, Clozapine decreases smoking in patients with chronic schizophrenia, Biological Psychiatry, vol.37, issue.8, pp.550-552, 1995.
DOI : 10.1016/0006-3223(94)00365-A

J. P. Mcevoy, O. Freudenreich, and E. D. Levin, Haloperidol increases smoking in patients with schizophrenia, Psychopharmacology, vol.48, issue.1, pp.124-126, 1995.
DOI : 10.1007/BF02246063

R. S. Mcintyre, J. K. Soczynska, J. Z. Kornaski, and S. H. Kennedy, The effect of antidepressants on glucose homeostasis and insulin sensitivity: synthesis and mechanisms, Expert Opinion on Drug Safety, vol.275, issue.1, pp.157-168, 2006.
DOI : 10.1016/S1474-4422(04)00681-7

T. Mclaughlin, F. Abbasi, K. Cheal, J. Chu, C. Lamendola et al., Use of Metabolic Markers To Identify Overweight Individuals Who Are Insulin Resistant, Annals of Internal Medicine, vol.139, issue.10, pp.802-811, 2003.
DOI : 10.7326/0003-4819-139-10-200311180-00007

J. L. Megna, T. L. Schwartz, and U. A. Siddiqui, Obesity in adults with serious and persistent mental illness: a review of postulated mechanisms and current interventions, Annals of Clinical Psychiatry, vol.23, issue.2, pp.131-140, 2011.

K. I. Melkersson, A. L. Hulting, and K. E. Brismar, Elevated Levels of Insulin, Leptin, and Blood Lipids in Olanzapine-Treated Patients With Schizophrenia or Related Psychoses, The Journal of Clinical Psychiatry, vol.61, issue.10, pp.742-749, 2000.
DOI : 10.4088/JCP.v61n1006

S. Mendis and A. Banerjee, Cardiovascular disease: equity and social determinants Equity, social determinants and public health programmes, 2010.

M. Menza, B. Vreeland, S. Minsky, M. Gara, D. R. Radler et al., Managing Atypical Antipsychotic???Associated Weight Gain, The Journal of Clinical Psychiatry, vol.65, issue.4, pp.471-477, 2004.
DOI : 10.4088/JCP.v65n0404

J. Meyer, Novel Antipsychotics and Severe Hyperlipidemia, Journal of Clinical Psychopharmacology, vol.21, issue.4, pp.369-374, 2001.
DOI : 10.1097/00004714-200108000-00003

J. M. Meyer and C. E. Koro, The effects of antipsychotic therapy on serum lipids: a comprehensive review, Schizophrenia Research, vol.70, issue.1, pp.1-17, 2004.
DOI : 10.1016/j.schres.2004.01.014

J. M. Meyer, H. A. Nasrallah, J. P. Mcevoy, D. C. Goff, S. M. Davis et al., The Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Trial: Clinical comparison of subgroups with and without the metabolic syndrome, Schizophrenia Research, vol.80, issue.1, pp.9-18, 2005.
DOI : 10.1016/j.schres.2005.07.015

J. M. Meyer, V. G. Davis, J. P. Mcevoy, D. C. Goff, H. A. Nasrallah et al., Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1, Schizophrenia Research, vol.103, issue.1-3, pp.104-109, 2008.
DOI : 10.1016/j.schres.2008.04.023

J. M. Meyer, V. G. Davis, J. P. Mcevoy, D. C. Goff, H. A. Nasrallah et al., Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1, Schizophrenia Research, vol.101, issue.1-3, pp.273-286, 2008.
DOI : 10.1016/j.schres.2007.12.487

A. J. Mitchell and D. Lawrence, Revascularisation and mortality rates following acute coronary syndromes in people with severe mental illness: comparative meta-analysis, The British Journal of Psychiatry, vol.198, issue.6, pp.434-441, 2011.
DOI : 10.1192/bjp.bp.109.076950

P. Monteleone, M. Fabrazzo, and M. Et-maj, Plasma Leptin and Antipsychotic-Induced Body Weight Gain, Neuropsychopharmacology, vol.22, issue.9, p.1769, 2005.
DOI : 10.1038/sj.npp.1300792

P. Monteleone, M. Fabrazzo, A. Tortorella, L. Pia, S. Maj et al., Pronounced Early Increase in Circulating Leptin Predicts a Lower Weight Gain During Clozapine Treatment, Journal of Clinical Psychopharmacology, vol.22, issue.4, pp.424-426, 2002.
DOI : 10.1097/00004714-200208000-00015

E. H. Morrato, J. W. Newcomer, S. Kamat, O. Baser, J. Harnett et al., Metabolic Screening After the American Diabetes Association's Consensus Statement on Antipsychotic Drugs and Diabetes, Diabetes Care, vol.32, issue.6, pp.1037-1042, 2009.
DOI : 10.2337/dc08-1720

S. Mukherjee, P. Decina, V. Bocola, F. Saraceni, and P. L. Scapicchio, Diabetes mellitus in schizophrenic patients, Comprehensive Psychiatry, vol.37, issue.1, pp.68-73, 1996.
DOI : 10.1016/S0010-440X(96)90054-1

D. Muller, K. Barkow, and S. Kovalenko, Suicide attempts in schizophrenia and affective disorders with relation to some specific demographical and clinical characteristics, European Psychiatry, vol.20, issue.1, pp.65-69, 2005.
DOI : 10.1016/j.eurpsy.2004.06.024

H. A. Nasrallah, J. M. Meyer, D. C. Goff, J. P. Mcevoy, S. M. Davis et al., Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline, Schizophrenia Research, vol.86, issue.1-3, pp.15-22, 2006.
DOI : 10.1016/j.schres.2006.06.026

H. Nasrallah, A review of the effect of atypical antipsychotics on weight, Psychoneuroendocrinology, vol.28, pp.83-96, 2003.
DOI : 10.1016/S0306-4530(02)00114-2

C. B. Nemeroff, Dosing the antipsychotic medication olanzapine, Journal of Clinical Psychiatry, vol.58, issue.10, pp.45-49, 1997.

J. W. Newcomer, D. W. Haupt, R. Fucetola, A. K. Melson, J. A. Schweiger et al., Abnormalities in Glucose Regulation During Antipsychotic Treatment of Schizophrenia, Archives of General Psychiatry, vol.59, issue.4, pp.337-345, 2002.
DOI : 10.1001/archpsyc.59.4.337

J. W. Newcomer, H. A. Nasrallah, and A. D. Loebel, The Atypical Antipsychotic Therapy and Metabolic Issues National Survey, Journal of Clinical Psychopharmacology, vol.24, pp.1-6, 2004.
DOI : 10.1097/01.jcp.0000142281.85207.d5

J. W. Newcomer, Second-Generation (Atypical) Antipsychotics and Metabolic Effects, CNS Drugs, vol.161, issue.4, pp.1-93, 2005.
DOI : 10.2165/00023210-200519001-00001

J. W. Newcomer, Metabolic consideration in the use of antipsychotic medications: a review of recent evidence, Journal of clinical Psychiatry, vol.68, issue.S1, pp.20-27, 2007.

J. W. Newcomer, Metabolic syndrome and mental illness, American Journal of Managed Care, vol.13, issue.S7, pp.170-177, 2007.

J. W. Newcomer, J. M. Meyer, R. A. Baker, J. M. Eudicone, A. Pikalov et al., Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine, Schizophrenia Research, vol.106, issue.2-3, pp.300-307, 2008.
DOI : 10.1016/j.schres.2008.09.002

S. C. Newman and R. C. Bland, Mortality in a cohort of patients with schizophrenia: a record linkage study, Canadian Journal of Psychiatry, vol.36, issue.4, pp.239-245, 1991.

M. Ng, T. Fleming, M. Robinson, and B. Thomson, Global, regional, and national prevalence of overweight and obesity in children and adults during 1980???2013: a systematic analysis for the Global Burden of Disease Study 2013, The Lancet, vol.384, issue.9945, pp.766-781, 2014.
DOI : 10.1016/S0140-6736(14)60460-8

B. G. Nordestgaard, M. Benn, and P. Schnohr, Nonfasting Triglycerides and Risk of Myocardial Infarction, Ischemic Heart Disease, and Death in Men and Women, JAMA, vol.298, issue.3, pp.299-308, 2007.
DOI : 10.1001/jama.298.3.299

D. Novick, J. M. Haro, E. Perrin, D. Suarez, and J. Marques-texeira, Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study, European Neuropsychopharmacology, vol.19, issue.8, pp.542-550, 2009.
DOI : 10.1016/j.euroneuro.2009.03.003

. Obepi-roche, Enquête épidémiologique de reference sur l'évolution de l'obésité et du surpoids en France

O. Mondiale-de and L. Santé, Obésité et surpoids. Aide-mémoire n°311, janvier, 2015.

D. P. Osborn, The poor physical health of people with mental illness, Western Journal of Medicine, vol.175, issue.5, pp.329-332, 2001.
DOI : 10.1136/ewjm.175.5.329

D. P. Osborn, I. Nazareth, and M. B. King, Risk for coronary heart disease in people with severe mental illness: Cross-sectional comparative study in primary care, The British Journal of Psychiatry, vol.188, issue.3, pp.271-277, 2006.
DOI : 10.1192/bjp.bp.104.008060

D. P. Osborn, G. Levy, I. Nazareth, I. Petersen, A. Islam et al., Relative Risk of Cardiovascular and Cancer Mortality in People With Severe Mental Illness From the United Kingdom's General Practice Research Database, Archives of General Psychiatry, vol.64, issue.2, pp.242-249, 2007.
DOI : 10.1001/archpsyc.64.2.242

U. Osby, N. Correia, L. Brandt, A. Ekbom, and P. Sparen, Time trends in schizophrenia mortality in Stockholm County, Sweden: cohort study, BMJ, vol.321, issue.7259, pp.483-484, 2000.
DOI : 10.1136/bmj.321.7259.483

U. Osby, N. Correia, L. Brandt, A. Ekbom, and P. Sparen, Mortality and causes of death in schizophrenia in Stockholm County, Sweden, Schizophrenia Research, vol.45, issue.1-2, pp.21-28, 2000.
DOI : 10.1016/S0920-9964(99)00191-7

S. Park, D. Ross-degnan, A. S. Adams, J. Sabin, P. Kanavos et al., Effect of switching antipsychotics on antiparkinsonian medication use in schizophrenia: Population-based study, The British Journal of Psychiatry, vol.187, issue.2, pp.137-179, 2005.
DOI : 10.1192/bjp.187.2.137

R. Pearsall, D. J. Smith, A. Pelosi, and J. Geddes, Exercise therapy in adults with serious mental illness: a systematic review and meta-analysis, BMC Psychiatry, vol.18, issue.6, 2014.
DOI : 10.3109/09638230903111114

T. A. Pearson, J. Laurora, and H. Chu, The Lipid Treatment Assessment Project (L-TAP), Archives of Internal Medicine, vol.160, issue.4, pp.459-467, 2000.
DOI : 10.1001/archinte.160.4.459

J. Pickup, M. Mattock, G. Chusney, and D. Burt, NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X, Diabetologia, vol.23, issue.2, pp.1286-92, 1997.
DOI : 10.1007/s001250050822

M. H. Porter, A. Cutchins, J. B. Fine, Y. Bai, and M. Digirolamo, Effects of TNF-?? on glucose metabolism and lipolysis in adipose tissue and isolated fat-cell preparations, Journal of Laboratory and Clinical Medicine, vol.139, issue.3, pp.140-146, 2002.
DOI : 10.1067/mlc.2002.121552

S. E. Purdon, A. Malla, A. Labelle, and W. Lit, Neuropsychological change in patients with schizophrenia after treatment with quetiapine or haloperidol, Journal of Psychiatry & Neuroscience, vol.26, pp.137-149, 2001.

E. D. Radomsky, G. L. Haas, and J. J. Mann, Suicidal Behavior in Patients With Schizophrenia and Other Psychotic Disorders, American Journal of Psychiatry, vol.156, issue.10, pp.1590-1595, 1999.
DOI : 10.1176/ajp.156.10.1590

W. A. Ray, C. P. Chung, K. T. Murray, K. Hall, and C. M. Stein, Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death, New England Journal of Medicine, vol.360, issue.3, pp.225-260, 2009.
DOI : 10.1056/NEJMoa0806994

G. M. Reaven and . Banting-lecture, Role of Insulin Resistance in Human Disease, Diabetes, vol.37, issue.12, pp.1595-1607, 1988.
DOI : 10.2337/diab.37.12.1595

G. M. Reaven, The Metabolic Syndrome: Requiescat in Pace, Clinical Chemistry, vol.51, issue.6, pp.931-938, 2005.
DOI : 10.1373/clinchem.2005.048611

D. A. Redelmeier, H. T. Siew, and G. L. Booth, The Treatment of Unrelated Disorders in Patients with Chronic Medical Diseases, New England Journal of Medicine, vol.338, issue.21, pp.1516-1520, 1998.
DOI : 10.1056/NEJM199805213382106

S. L. Reynolds and . Kirk, Metabolic side effects of antipsychotic drug treatment ??? pharmacological mechanisms, Pharmacology & Therapeutics, vol.125, issue.1, pp.169-179, 2010.
DOI : 10.1016/j.pharmthera.2009.10.010

D. G. Robinson, M. G. Woerner, J. M. Alvir, and R. M. Bilder, Predictors of medication discontinuation by patients with first-episode schizophrenia and schizoaffective disorder, Schizophrenia Research, vol.57, issue.2-3, pp.209-219, 2002.
DOI : 10.1016/S0920-9964(01)00312-7

O. Ruetsch, A. Viala, H. Bardou, P. Martin, and M. N. Vacheron, Prise de poids pharmaco-induite par les psychotropes et sa prise en charge : revue des donn??es de la litt??rature, L'Enc??phale, vol.31, issue.4, pp.507-516, 2005.
DOI : 10.1016/S0013-7006(05)82412-1

C. Rummel-kluge, K. Komossa, S. Schwarz, and H. Hunge, Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: A systematic review and meta-analysis, Schizophrenia Research, vol.123, issue.2-3, pp.225-233, 2010.
DOI : 10.1016/j.schres.2010.07.012

M. C. Ryan and J. H. Thakore, Physical consequences of schizophrenia and its treatment, Life Sciences, vol.71, issue.3, pp.239-257, 2002.
DOI : 10.1016/S0024-3205(02)01646-6

M. C. Ryan, S. Flanagan, U. Kinsella, F. Keeling, and J. H. Thakore, The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naïve patients with schizophrenia, Life Sciences, vol.74, 1999.

M. C. Ryan, N. Sharifi, R. Condren, and J. H. Thakore, Evidence of basal pituitary???adrenal overactivity in first episode, drug na??ve patients with schizophrenia, Psychoneuroendocrinology, vol.29, issue.8, pp.1065-1070, 2004.
DOI : 10.1016/j.psyneuen.2003.08.011

G. S. Sachs and C. Guille, Weight gain associated with use of psychotropic medications, Journal of Clinical Psychiatry, vol.60, pp.16-19, 1999.

S. Saha, D. Chant, and J. Mc-grath, A systematic review of mortality in schizophrenia. Is the differential mortality gap worsening over time? Archive General of, Psychiatry, vol.64, pp.1123-1154, 2007.

A. J. Scheen and M. De-hert, Drug-induced diabetes mellitus: the example of atypical antipsychotics, Revue Medicale de Liege, vol.60, pp.5-6, 2005.

A. Scheen and M. De-hert, Abnormal glucose metabolism in??patients treated with antipsychotics, Diabetes & Metabolism, vol.33, issue.3, pp.169-175, 2007.
DOI : 10.1016/j.diabet.2007.01.003

D. Schoepf, R. Potluri, H. Uppal, A. Natalwala, P. Narendran et al., Type-2 diabetes mellitus in schizophrenia: Increased prevalence and major risk factor of excess mortality in a naturalistic 7-year follow-up, European Psychiatry, vol.27, issue.1, pp.33-42, 2012.
DOI : 10.1016/j.eurpsy.2011.02.009

M. W. Schwartz, S. C. Woods, D. Porte, . Jr, R. J. Seeley et al., Central nervous system control of food intake, Nature, vol.404, issue.6778, pp.661-671, 2000.

C. F. Semenkovich, Insulin resistance and atherosclerosis, Journal of Clinical Investigation, vol.116, issue.7, pp.1813-1835, 2006.
DOI : 10.1172/JCI29024DS1

A. Simard, Effets des troubles métaboliques sur la qualité de vie des personnes atteintes de problème de santé mentale, Partenaire, vol.19, issue.4, pp.9-12, 2011.

H. O. Steinberg and A. D. Baron, Vascular function, insulin resistance and fatty acids, Diabetologia, vol.45, issue.5, pp.623-657, 2002.
DOI : 10.1007/s00125-002-0800-2

M. Strassnig and J. S. Brar, Nutritional Assessment of Patients With Schizophrenia: A Preliminary Study, Schizophrenia Bulletin, vol.29, issue.2, pp.393-397, 2003.
DOI : 10.1093/oxfordjournals.schbul.a007013

D. M. Taylor and R. Mcaskill, Atypical antipsychotics and weightgain - a systematic review, Acta Psychiatrica Scandinavica, vol.101, issue.6, pp.416-432, 2000.
DOI : 10.1034/j.1600-0447.2000.101006416.x

L. H. Tecott, L. M. Sun, S. F. Akana, A. M. Strack, D. H. Lowenstein et al., Eating disorder and epilepsy in mice lacking 5-HT2C serotonin receptors, Nature, vol.374, issue.6522, pp.542-546, 1995.
DOI : 10.1038/374542a0

J. H. Thakore, J. N. Mann, I. Vlahos, A. Martin, and R. H. Reznek, Increased visceral fat distribution in drug-naive and drug-free patients with schizophrenia, International Journal of Obesity, vol.26, issue.1, pp.137-141, 2002.
DOI : 10.1038/sj.ijo.0801840

J. H. Thakore, Metabolic disturbance in first-episode schizophrenia, The British Journal of Psychiatry, vol.184, issue.47, pp.76-79, 2004.
DOI : 10.1192/bjp.184.47.s76

J. H. Thakore, Physical health of patients with schizophrenia, Psychiatry, vol.4, issue.11, pp.58-60, 2005.
DOI : 10.1383/psyt.2005.4.11.58

F. M. Theisen, A. Linden, F. Geller, and H. Schäfer, Prevalence of obesity in adolescent and young adult patients with and without schizophrenia and in relationship to antipsychotic medication, Journal of Psychiatric Research, vol.35, issue.6, pp.339-345, 2001.
DOI : 10.1016/S0022-3956(01)00041-3

D. Tidemalm, M. Margda-waern, C. G. Stefansson, S. Elofsson, and B. Runeson, Excess mortality in persons with severe mental disorder in Sweden: a cohort study of 12,103 individuals with and without contact with psychiatric services, Clinical Practice and Epidemiology in Mental Health, vol.4, pp.4-23, 2008.

E. Tison, Syndrome métabolique : diagnostic, conséquences cardiaques et vasculaires, EMC-Cardiologie Angéiologie, pp.423-430, 2005.

C. Tsatsanis, V. Zacharioudaki, A. Androulidaki, E. Dermitzaki, I. Charalampopoulos et al., Peripheral Factors in the Metabolic Syndrome: The Pivotal Role of Adiponectin, Annals of the New York Academy of Sciences, vol.50, issue.1, pp.185-95, 2006.
DOI : 10.1210/jc.2003-031826

D. Vancampfort, J. Knapen, M. Probst, W. R. Van, S. Deckx et al., Considering a frame of reference for physical activity research related to the cardiometabolic risk profile in schizophrenia, Psychiatry Research, vol.177, issue.3, pp.271-279, 2010.
DOI : 10.1016/j.psychres.2010.03.011

D. Vancampfort, M. Probst, T. Scheewe, D. Herdt, A. Sweers et al., Relationships between physical fitness, physical activity, smoking and metabolic and mental health parameters in people with schizophrenia, Psychiatry Research, vol.207, issue.1-2, pp.25-32, 2013.
DOI : 10.1016/j.psychres.2012.09.026

L. F. Van-gaal, Long-term health considerations in schizophrenia: Metabolic effects and the role of abdominal adiposity, European Neuropsychopharmacology, vol.16, pp.142-148, 2006.
DOI : 10.1016/j.euroneuro.2006.06.005

L. F. Van-gaal, I. L. Mertens, and C. E. De-block, Mechanisms linking obesity with cardiovascular disease, Nature, vol.105, issue.7121, pp.875-80, 2006.
DOI : 10.1038/nature05487

J. Vague, The degree of masculine differentiation of obesities. A factor determining predisposition to diabetes, atherosclerosis, gout and uric calculous disease, American Journal of Clinical Nutrition International Journal of Psychiatry in Medicine, vol.4, issue.25, pp.20-34, 1956.

J. L. Waddington, H. A. Youssef, and . Kinsella, Mortality in schizophrenia. Antipsychotic polypharmacy and absence of adjunctive anticholinergics over the course of a 10-year prospective study, The British Journal of Psychiatry, vol.173, issue.4, pp.325-334, 1998.
DOI : 10.1192/bjp.173.4.325

L. E. Wagenknecht, C. D. Langefeld, A. L. Scherzinger, J. M. Norris, S. M. Haffner et al., Insulin Sensitivity, Insulin Secretion, and Abdominal Fat: The Insulin Resistance Atherosclerosis Study (IRAS) Family Study, Diabetes, vol.52, issue.10, pp.2490-2496, 2003.
DOI : 10.2337/diabetes.52.10.2490

E. Walker, V. Mittal, and K. Tessner, Stress and the Hypothalamic Pituitary Adrenal Axis in the Developmental Course of Schizophrenia, Annual Review of Clinical Psychology, vol.4, issue.1, pp.189-216, 2008.
DOI : 10.1146/annurev.clinpsy.4.022007.141248

C. Wang, Y. Xiang, and Y. Weng, Cigarette Smoking in Patients with Schizophrenia in China: Prospective, Multicentre Study, Australian & New Zealand Journal of Psychiatry, vol.18, issue.5, pp.456-62, 2010.
DOI : 10.1016/j.ahj.2005.02.007

M. Wang, J. Tong, G. Zhu, G. Liang, H. Yan et al., Metformin for treatment of antipsychotic-induced weight gain: A randomized, placebo-controlled study, Schizophrenia Research, vol.138, issue.1, pp.54-57, 2012.
DOI : 10.1016/j.schres.2012.02.021

P. S. Wang, R. J. Glynn, and D. A. Ganz, Clozapine Use and Risk of Diabetes Mellitus, Journal of Clinical Psychopharmacology, vol.22, issue.3, pp.236-279, 2002.
DOI : 10.1097/00004714-200206000-00002

S. G. Wannamethee, A. G. Shaper, and I. J. Perry, Smoking as a Modifiable Risk Factor for Type 2 Diabetes in Middle-Aged Men, Diabetes Care, vol.24, issue.9, pp.1590-1595, 2001.
DOI : 10.2337/diacare.24.9.1590

S. G. Wannamethee, A. G. Shaper, L. Lennon, and R. W. Morris, Metabolic Syndrome vs Framingham Risk Score for Prediction of Coronary Heart Disease, Stroke, and Type 2 Diabetes Mellitus, Archives of Internal Medicine, vol.165, issue.22, pp.2644-2650, 2005.
DOI : 10.1001/archinte.165.22.2644

P. Weiden, R. Aquila, and J. Standard, Atypical antipsychotic drugs and long-term outcome in schizophrenia, Journal of Clinical Psychiatry, vol.57, pp.53-60, 1996.

P. Weiden, J. Mackell, and D. Mcdonnell, Obesity as a risk factor for antipsychotic noncompliance, Schizophrenia Research, vol.66, issue.1, pp.51-57, 2004.
DOI : 10.1016/S0920-9964(02)00498-X

S. Weinmann, J. Read, and V. Aderhold, Influence of antipsychotics on mortality in schizophrenia: Systematic review, Schizophrenia Research, vol.113, issue.1, pp.1-11, 2009.
DOI : 10.1016/j.schres.2009.05.018

R. L. Weinsier, G. R. Hunter, A. F. Heini, M. I. Goran, and S. M. Sell, The etiology of obesity: relative contribution of metabolic factors, diet, and physical activity, The American Journal of Medicine, vol.105, issue.2, pp.145-150, 1998.
DOI : 10.1016/S0002-9343(98)00190-9

T. Wetterling, Bodyweight Gain with Atypical Antipsychotics, Drug Safety, vol.62, issue.1, pp.59-73, 2001.
DOI : 10.2165/00002018-200124010-00005

J. M. Williams, D. M. Ziedonis, and F. Abanye, Increased nicotine and cotinine levels in smokers with schizophrenia and schizoaffective disorder is not a metabolic effect, Schizophrenia Research, vol.79, issue.2-3, pp.323-335, 2005.
DOI : 10.1016/j.schres.2005.04.016

D. A. Wirshing, J. A. Boyd, L. R. Meng, J. S. Ballon, S. R. Marder et al., The Effects of Novel Antipsychotics on Glucose and Lipid Levels, The Journal of Clinical Psychiatry, vol.63, issue.10, pp.856-865, 2002.
DOI : 10.4088/JCP.v63n1002

A. Wysoki?ski, M. Kowman, and I. K?oszewska, The prevalence of metabolic syndrome and Framingham cardiovascular risk scores in adult inpatients taking antipsychotics -a retrospective medical records review.Psychiatria Danubia, pp.314-336, 2012.

J. K. Young and D. A. Foster, Cardiovascular procedures in patients with mental disorders, JAMA, vol.283, pp.3198-3199, 2000.

R. B. Zipursky, H. Gu, A. I. Green, D. O. Perkins, M. F. Tohen et al., Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol, The British Journal of Psychiatry, vol.187, issue.6, pp.537-543, 2005.
DOI : 10.1192/bjp.187.6.537

Z. J. Zhang, Z. J. Yao, W. Liu, Q. Fan, and G. P. Et-reynolds, Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: Magnetic resonance imaging study of previously untreated people with schizophrenia, The British Journal of Psychiatry, vol.184, issue.1, pp.58-62, 2004.
DOI : 10.1192/bjp.184.1.58

P. L. Zhang, J. M. Santos, J. Newcomer, B. A. Pelfrey, M. C. Johnson et al., Impact of atypical antipsychotics on quality of life, self-report of symptom severity, and demand of services in chronically psychotic patients, Schizophrenia Research, vol.71, issue.1, pp.137-144, 2004.
DOI : 10.1016/j.schres.2003.11.005

U. Zimmermann, T. Kraus, H. Himmerich, A. Schuld, and T. Pollmächer, Epidemiology, implications and mechanisms underlying drug-induced weight gain in psychiatric patients, Journal of Psychiatric Research, vol.37, issue.3, pp.193-220, 2003.
DOI : 10.1016/S0022-3956(03)00018-9